EA202091092A1 - DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS - Google Patents
DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLSInfo
- Publication number
- EA202091092A1 EA202091092A1 EA202091092A EA202091092A EA202091092A1 EA 202091092 A1 EA202091092 A1 EA 202091092A1 EA 202091092 A EA202091092 A EA 202091092A EA 202091092 A EA202091092 A EA 202091092A EA 202091092 A1 EA202091092 A1 EA 202091092A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cells
- mobilization
- compositions
- stem cells
- dosed administration
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Настоящее изобретение относится к композициям и способам, применимым для мобилизации популяций гемопоэтических стволовых клеток и клеток-предшественников донора, а также для определения того, подходят ли образцы мобилизованных клеток для выделения с целью наращивания ex vivo и/или терапевтического применения. В соответствии с композициями и способами, описанными в настоящем документе, мобилизованные гемопоэтические стволовые клетки и клетки-предшественники могут быть изъяты у донора и введены пациенту для лечения различных ассоциированных со стволовыми клетками нарушений, в том числе включающих в себя болезни кроветворной системы, метаболические нарушения, злокачественные опухоли и аутоиммунные заболевания. Согласно определенным вариантам осуществления композиции и способы, описанные в настоящем документе, приводят к мобилизации популяции CD34dim клеток, которые обладают иммуносупрессирующими эффектами и которые могут снизить частоту возникновения реакции "трансплантат против хозяина".The present invention relates to compositions and methods useful for mobilizing populations of hematopoietic stem cells and donor progenitor cells, as well as for determining whether samples of mobilized cells are suitable for isolation for ex vivo expansion and / or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem cells and progenitor cells can be removed from a donor and administered to a patient for the treatment of various stem cell-associated disorders, including diseases of the hematopoietic system, metabolic disorders, malignant tumors and autoimmune diseases. In certain embodiments, the compositions and methods described herein result in the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft versus host disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773954P | 2018-11-30 | 2018-11-30 | |
PCT/US2018/064335 WO2019113375A2 (en) | 2017-12-06 | 2018-12-06 | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202091092A1 true EA202091092A1 (en) | 2020-10-09 |
Family
ID=73129245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202091092A EA202091092A1 (en) | 2018-11-30 | 2018-12-06 | DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202091092A1 (en) |
-
2018
- 2018-12-06 EA EA202091092A patent/EA202091092A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Szabó et al. | Licensing by inflammatory cytokines abolishes heterogeneity of immunosuppressive function of mesenchymal stem cell population | |
Terai et al. | Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis | |
Liang et al. | Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives | |
Shabbir et al. | Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair | |
ES2756336T3 (en) | Methods that modulate the immunoregulatory effect of stem cells | |
Quijada et al. | Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells | |
Ilmer et al. | Two sides of the same coin: stem cells in cancer and regenerative medicine | |
EA201490911A1 (en) | METHODS OF TREATMENT OF MALIGNANT TUMORS WITH THE USE OF ORAL COMPOSITIONS OF CYTIDINE ANALOGUES | |
Ankersmit et al. | Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium | |
EA200700886A1 (en) | CONNECTION OF TIADIAZOLE AND ITS APPLICATION | |
JP6898706B2 (en) | Mesenchymal stem cells to treat liver disease | |
Liang et al. | Conditioned medium from induced pluripotent stem cell-derived mesenchymal stem cells accelerates cutaneous wound healing through enhanced angiogenesis | |
MX2020005878A (en) | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells. | |
CL2020003319A1 (en) | Chimeric growth factor receptors | |
Zhang et al. | Human-derived normal mesenchymal stem/stromal cells in anticancer therapies | |
Oliveira et al. | A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation | |
EA202092459A1 (en) | INTERLEUKIN 12 HYBRID PROTEINS, COMPOSITIONS AND METHODS OF THERAPEUTIC APPLICATION, WHICH INCLUDE THEM | |
Tyndall et al. | Stem cell transplantation and mesenchymal cells to treat autoimmune diseases | |
Kim et al. | PIN1 suppresses the hepatic differentiation of pulp stem cells via Wnt3a | |
Deng et al. | Up-regulation of CXCR4 in rat umbilical mesenchymal stem cells induced by serum from rat with acute liver failure promotes stem cells migration to injured liver tissue | |
Geng et al. | HGF-modified dental pulp stem cells mitigate the inflammatory and fibrotic responses in paraquat-induced acute respiratory distress syndrome | |
Eom et al. | Mesenchymal stem cell therapy for liver disease: current status and future perspectives | |
Lai et al. | A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis | |
Chang et al. | From Hair to Colon: Hair Follicle-Derived MSCs Alleviate Pyroptosis in DSS-Induced Ulcerative Colitis by Releasing Exosomes in a Paracrine Manner | |
Alanazi | COVID-19 and the role of stem cells |